Study identifies immune markers for chemotherapy benefit in early-stage breast cancer

AI-Powered Analysis Reveals Immune Marker to Predict Chemotherapy Benefit in Breast Cancer

Key Insight: AI analysis of immune cells in the tumor microenvironment has identified a specific marker that could help determine which early-stage breast cancer patients can safely skip chemotherapy.

New research published in Nature Communications has identified immune markers that could revolutionize treatment decisions for patients with early-stage ER+HER2- breast cancer. Led by RCSI University of Medicine and Health Sciences and University College Dublin (UCD), the study utilized AI-based methods to analyze immune cells, potentially sparing thousands of patients from unnecessary chemotherapy.

ER+HER2- breast cancer accounts for approximately 70% of all breast cancer diagnoses. Current risk assessment tools frequently yield intermediate results, leaving both patients and clinicians in a state of uncertainty. This ambiguity often leads to the precautionary prescription of chemotherapy, even when its benefits may be minimal for certain individuals.

The study specifically used samples from a randomized trial that compared hormone-blocking therapy alone versus hormone-blocking therapy combined with chemotherapy in Irish patients classified with intermediate risk scores.

Researchers discovered a critical clue hidden within the tumor's immediate surroundings. A high density of cytotoxic T-cells in the tissue surrounding a tumor was associated with poorer outcomes when those patients were treated with chemotherapy. This finding suggests that the density of these immune cells could serve as a powerful predictive marker.

“AI-based analysis of the tumor microenvironment can improve precision and equity of treatment,” said Professor Darran O'Connor, highlighting the potential for this technology to transform clinical practice.

Dr. Zak Kinsella elaborated on the findings: “The density of cytotoxic T-cells was a strong predictor of treatment response.”

A key advantage of this method is its practicality. The approach uses standard tissue samples that are already processed as part of routine care, which could significantly facilitate its adoption in hospitals and clinics worldwide.

Before this technology can be implemented in patient care, further validation is required. “Further validation in larger studies is required before clinical implementation,” noted Professor William Gallagher.

In the meantime, RCSI and UCD have filed a patent for the technology and are actively seeking to commercialize it. This effort is supported by funding from the ARC Hub for HealthTech, which will fuel further development and refinement of the AI-based analysis.